Bibliografía del artículo
1. Jellinger K. Pathology of parkinsonism. In: Fahn S et al eds. Recent developments in Parkinson's disease. Raven Press, New York, pp. 33-66, 1986.
2. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 38(Suppl.2):2-7, 1997.
3. Goodman LS, Gillman A. The pharmacological basis of therapeutics. Section: Relationship between the nervous and the endocrine system. 11th edition. Brunton LL Ed. McGraw-Hill Press, New York, 2007.
4. Nonogaki K. New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia 43(5):533-49, 2000.
5. Ahren B. Autonomic regulation of islet hormone secretion-implications for health and disease. Diabetologia 43:393-410, 2000.
6. Ahren B, Wierup N, Sundler F. Neuropeptides and the regulation of islet function. Diabetes 55(Suppl.2):98-107, 2006.
7. Niijima A. Neural control of blood glucose level. Jpn J Physiol 36(5):827-41, 1986.
8. Attvall S, Fowelin J, von Schenck H, Lager I, Smith U. Insulin resistance in type 1 (insulin-dependent) diabetes following hypoglycaemia--evidence for the importance of beta-adrenergic stimulation. Diabetologia 30(9):691-7, 1987.
9. Yamaguchi N. Sympathoadrenal system in neuroendocrine control of glucose: mechanisms involved in the liver, pancreas, and adrenal gland under hemorrhagic and hypoglycemic stress. Can J Physiol Pharmacol 70(2):167-206, 1992.
10. Jackson PA, Pagliassotti MJ, Shiota M, Neal DW, Cardin S, Cherrington AD. Effects of vagal blockade on counterregulatory response to insulin-induced hypoglycemia in the dog. Am J Physiol 273:1178-88, 1997.
11. Fabris SE, Thorburn A, Litchfield A, Proietto J. Effect of parasympathetic denervation of liver and pancreas on glucose kinetics in man. Metabolism 45(8):987-91, 1996.
12. Palatini P, Longo D, Zaetta V, Perkovic D, Garbelotto R, Pessina AC. Evolution of blood pressure and cholesterol in stage 1 hypertension: role of autonomic nervous system activity. J Hypertens 24(7):1375-81, 2006.
13. O'Donnell L, Owens D, McGee C, et al. Effects of catecholamines on serum lipoproteins of normally fed and cholesterol-fed rabbits. Metabolism 37(10):910-5, 1988.
14. O'Meara NM, Devery RA, Owens D, Collins PB, Johnson AH, Tomkin GH. Alterations in cellular cholesterol metabolism following administration of 6-hydroxydopamine to rabbits. Br J Pharmacol 105(2):495-9, 1992.
15. Scott LM, Tomkin GH. Cholesterol metabolism: regulatory effects of the vagus in the normal and diabetic animal. Diabetes Res 2(6):313-7, 1985.
16. Goldstein DS, Holmes CS, Dendi R, Bruce SR, Li ST. Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology 58:1247-55, 2002.
17. Camerlingo M, Aillon C, Bottacchi E, et al. Parasympathetic assessment in Parkinson's disease. Adv Neurol 45:267-9, 1987.
18. Oka H, Mochio S, Onouchi K, Morita M, Yoshioka M, Inoue K. Cardiovascular dysautonomia in de novo Parkinson's disease. J Neurol Sci 241(1-2):59-65, 2006.
19. Goldstein DS. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol 2(11):669-76, 2003.
20. Senard JM, Rai S, Lapeyre-Mestre M, et al. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry 63(5):584-9, 1997.
21. Barbeau A, Gillo Joffroy L, Boucher R, Novaczynski W, Genest J. Renin-Aldosterone system in Parkinson's disease. Science 165:291-2, 1969.
22. Bellomo G, Santambrogio L, Fiacconi M, Scarponi AM, Ciuffetti G. Plasma profiles of adrenocorticotropic hormone, cortisol, growth hormone and prolactin in patients with untreated Parkinson's disease. J Neurol 238(1):19-22, 1991.
23. Carmichael SW, Wilson RJ, Brimijoin WS, et al. Decreased catecholamines in the adrenal medulla of patients with parkinsonism. N Engl J Med 28:254, 1988.
24. Paquot N, Schneiter P, Jequier E, Tappy L. Effects of glucocorticoids and sympathomimetics agents on basal and insulin-stimulated glucose metabolism. Clin Physiol 15(3):231-40, 1995.
25. Goldstein DS, Robertson D, Esler M, Straus SE, Eisenhofer G. Dysautonomias: clinical disorders of the autonomic nervous system. Ann Intern Med 137(9):753-63, 2002.
26. Scigliano G, Musicco M, Soliveri P, Piccolo I, Ronchetti G, Girotti F. Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke 37:1184-8, 2006.
27. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 17:427-42, 1967.
28. Mannelli M, Gheri RG, Selli C, et al. A study on human adrenal secretion. Measurement of epinephrine, norepinephrine, dopamine and cortisol in peripheral and adrenal venous blood under surgical stress. J Endocrinol Invest 5(2):91-5, 1982.
29. Rahn KH, Barenbrock M, Hausberg M. The sympathetic nervous system in the pathogenesis of hypertension. J Hypertension 17(S 3):11-14, 1999.
30. Fratiglioni L, Wang XH. Smoking and Parkinson's and Alzheimer's disease: review of the epidemiological studies. Behav Brain Res 113(1-2):117-20, 2000.
31. Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid concentrations: an analysis of published data. BMJ 298(6676):784-8, 1989.
32. Mannelli M, Pupili C, Lanzillotti R, Ianni L, Bellini F, Sergio M. Role of endogenous dopamine in modulating sympathetic-adrenal activity in humans. Hypertens Res 18(Suppl.1):79-86, 1995.
33. Whitsett TL, Halushka PV, Goldberg LI. Attenuation of postganglionic sympathetic nerve activity by L-dopa. Circ Res 27:561-70, 1970.
34. Murphy MB. Dopamine: a role in the pathogenesis and treatment of hypertension. J Hum Hypertens 14(1):S47-50, 2000.
35. Finlay GD, Whitsett TL, Cucinell EA, Goldberg L. Augmentation of sodium and potassium excretion, glomerular filtration rate and renal plasma flow by levodopa. N Engl J Med 284:865-870, 1971.
36. Sowers JR, Beck FW. Dopaminergic regulation of 18-hydroxycorticosterone and aldosterone secretion in man. Acta Endocrinol (Copenh) 102(2):258-64, 1983.
37. Barbieri C, Caldara R, Ferrari C, Crossignani RM, Recchia M. Inhibition of the renin-angiotensin-aldosterone system by L-dopa with and without inhibition of extracerebral dopa decarboxylase in man. Clin Sci (Lond) 61(2):187-90, 1981.
38. Golda V, Hilgertova J. Effect of terguride on insulin binding, insulinaemia, glucose tolerance and hyperlipaemia in lean SHR Koletsky rats. Physiol Res 46(6):439-42, 1997.
39. Cincotta AH, Meier AH, Cincotta Jr M. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs 8(10):1683-1707, 1999.
40. Saito I , Kawabe H, Hasegawa C, et al. Effect of L-dopa in young patients with hypertension. Angiology 42:691-5, 1991.
41. Dingemanse J, Kleinbloesem CH, Zurcher G, Wood ND, Crevoisier C. Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics. Br J Clin Pharmacol 44:41-8, 1997.
42. Scigliano G, Musicco M, Soliveri P, Piccolo I, Ronchetti G, Girotti F. Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke 37:1184-8, 2006.
43. Scigliano G, Ronchetti G, Girotti F, Musicco M. Sympathetic modulation by levodopa reduces vascular risk factors in Parkinson disease. Park Rel Dis 15(2):138-43, 2009.